Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial
- PMID: 10770145
- DOI: 10.1001/jama.283.14.1837
Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial
Abstract
Context: Despite the high prevalence, chronicity, and associated comorbidity of posttraumatic stress disorder (PTSD) in the community, few placebo-controlled studies have evaluated the efficacy of pharmacotherapy for this disorder.
Objective: To determine if treatment with sertraline hydrochloride effectively diminishes symptoms of PTSD of moderate to marked severity.
Design: Twelve-week, double-blind, placebo-controlled trial preceded by a 2-week, single-blind placebo lead-in period, conducted between May 1996 and June 1997.
Setting: Outpatient psychiatric clinics in 8 academic medical centers and 6 clinical research centers.
Patients: A total of 187 outpatients with a Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition diagnosis of PTSD and a Clinician Administered PTSD Scale Part 2 (CAPS-2) minimum total severity score of at least 50 at baseline (mean age, 40 years; mean duration of illness, 12 years; 73% were women; and 61.5% experienced physical or sexual assault).
Intervention: Patients were randomized to acute treatment with sertraline hydrochloride in flexible daily dosages of 50 to 200 mg/d, following 1 week at 25 mg/d (n=94); or placebo (n=93).
Main outcome measures: Baseline-to-end-point changes in CAPS-2 total severity score, Impact of Event Scale total score (IES), and Clinical Global Impression-Severity (CGI-S), and CGI-Improvement (CGI-I) ratings, compared by treatment vs placebo groups. Results Sertraline treatment yielded significantly greater improvement than placebo on 3 of the 4 primary outcome measures (mean change from baseline to end point for CAPS-2 total score, -33.0 vs -23.2 [P =.02], and for CGI-S, -1.2 vs -0.8 [P=.01]; mean CGI-I score at end point, 2.5 vs 3.0 [P=.02]), with the fourth measure, the IES total score, showing a trend toward significance (mean change from baseline to end point, -16.2 vs -12.1; P=.07). Using a conservative last-observation-carried-forward analysis, treatment with sertraline resulted in a responder rate of 53% at study end point compared with 32% for placebo (P=.008, with responder defined as >30% reduction from baseline in CAPS-2 total severity score and a CGI-I score of 1 [very much improved], or 2 [much improved]). Significant (P<.05) efficacy was evident for sertraline from week 2 on the CAPS-2 total severity score. Sertraline had significant efficacy vs placebo on the CAPS-2 PTSD symptom clusters of avoidance/numbing (P=.02) and increased arousal (P=.03) but not on reexperiencing/intrusion (P=.14). Sertraline was well tolerated, with insomnia the only adverse effect reported significantly more often than placebo (16.0% vs 4.3%; P=.01).
Conclusions: Our data suggest that sertraline is a safe, well-tolerated, and effective treatment for PTSD.
Comment in
-
Placebo effect in posttraumatic stress disorders.JAMA. 2000 Aug 2;284(5):563-4. doi: 10.1001/jama.284.5.563. JAMA. 2000. PMID: 10918693 No abstract available.
Similar articles
-
Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder.Arch Gen Psychiatry. 2001 May;58(5):485-92. doi: 10.1001/archpsyc.58.5.485. Arch Gen Psychiatry. 2001. PMID: 11343529 Clinical Trial.
-
A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder.Psychol Med. 2011 Oct;41(10):2159-66. doi: 10.1017/S0033291711000201. Epub 2011 Feb 24. Psychol Med. 2011. PMID: 21349225 Clinical Trial.
-
Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.J Clin Psychopharmacol. 2006 Jun;26(3):259-67. doi: 10.1097/01.jcp.0000222514.71390.c1. J Clin Psychopharmacol. 2006. PMID: 16702890 Clinical Trial.
-
Pharmacotherapy for anxiety and comorbid alcohol use disorders.Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007505. doi: 10.1002/14651858.CD007505.pub2. Cochrane Database Syst Rev. 2015. PMID: 25601826 Free PMC article. Review.
-
Antidepressant treatment of posttraumatic stress disorder.J Clin Psychiatry. 2000;61 Suppl 7:40-3. J Clin Psychiatry. 2000. PMID: 10795608 Review.
Cited by
-
Enhancing massed prolonged exposure with cannabidiol to improve posttraumatic stress disorder: Design and methodology of a pilot randomized clinical trial.Contemp Clin Trials Commun. 2024 Feb 15;38:101270. doi: 10.1016/j.conctc.2024.101270. eCollection 2024 Apr. Contemp Clin Trials Commun. 2024. PMID: 38404650 Free PMC article.
-
Breathing new life into PTSD-related sleep disorders!J Clin Sleep Med. 2024 Mar 1;20(3):335-336. doi: 10.5664/jcsm.11008. J Clin Sleep Med. 2024. PMID: 38156417 No abstract available.
-
Neural correlates of PTSD in women with childhood sexual abuse with and without PTSD and response to paroxetine treatment: A placebo-controlled, double-blind trial.J Affect Disord Rep. 2023 Dec;14:100615. doi: 10.1016/j.jadr.2023.100615. Epub 2023 Jun 24. J Affect Disord Rep. 2023. PMID: 38088987 Free PMC article.
-
The Factors Affecting Longitudinal Course of Posttraumatic Stress Disorder Symptoms in Sexual Assault Victims.Psychiatry Investig. 2023 Nov;20(11):1061-1068. doi: 10.30773/pi.2023.0077. Epub 2023 Nov 21. Psychiatry Investig. 2023. PMID: 37997334 Free PMC article.
-
Anxiety and Depression in Family Members of Critically Ill Covid-19 Inpatients: Brief Psychological Interventions via Telephone, an Exploratory Study.J Multidiscip Healthc. 2023 Nov 7;16:3319-3331. doi: 10.2147/JMDH.S434448. eCollection 2023. J Multidiscip Healthc. 2023. PMID: 37954471 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous